SGMT – sagimet biosciences inc. (US:NASDAQ)
Stock Stats
News
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024 [Yahoo! Finance]
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Form SC 13G/A Sagimet Biosciences Inc. Filed by: Point72 Asset Management, L.P.
Form SC 13G Sagimet Biosciences Inc. Filed by: Blue Owl Capital Holdings LP
Form SC 13G/A Sagimet Biosciences Inc. Filed by: HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Form SC 13G/A Sagimet Biosciences Inc. Filed by: BAKER BROS. ADVISORS LP
Form 8-K Sagimet Biosciences Inc. For: Nov 14
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.